Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus nephritis

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

- PMLiVE

Amgen plans acquisition of Rodeo Therapeutics

Deal could be worth over $700m including potential future milestone payments

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

- PMLiVE

J&J inks $6.5bn all-cash deal to acquire Momenta

Acquisition sees J&J gain access to portfolio of autoimmune disease treatments

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Moderna and GSK advance coronavirus vaccine candidates

Developments come amid rapidly growing cases across the globe

- PMLiVE

Researchers discover new antibiotic using AI

First antibiotic to be discovered using this method

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links